FilingSEC EDGAR6-K
Satellos Bioscience Completes Enrollment in Phase 2 DMD Trial
· SEC accepted
StagePhase 2
Filing content
Satellos Bioscience has completed patient enrollment for its Phase 2 clinical trial of forazapadin for Duchenne muscular dystrophy and expects to release topline data in the first quarter of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…